PMDAsafety guidance83% confidence
[YAKKYOKUKATA]Press Release regarding international activities related to Pharmacopoeia posted
Source: PMDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Aurobindo Pharma.
Regulatory Analysis
PMDA regulatory document relevant to this signal.
Supporting Context
- Therapeutic area
- Diabetes · SGLT2 Inhibitor
- Sub-indication
- General
Related signal: Aurobindo Pharma submits ANDA for Empagliflozin